Tilmovet 40 g/kg Premix for Medicated Feeding Stuff for Pigs and Rabbits

Summary of Product characteristics

                                Revised: October 2014
AN: 01383/2013
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Tilmovet 40 g/kg Premix for Medicated Feeding Stuff for Pigs and
Rabbits
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
40 g tilmicosin per kg
EXCIPIENTS:
For the full list of excipients: see section 6.1.
3.
PHARMACEUTICAL FORM
Premix for medicated feeding stuff
A yellowish tan to reddish tan free-flowing granular material.
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Pigs (weaned piglets and fattening pigs) and rabbits
4.2.
INDICATIONS FOR USE (SPECIFYING THE TARGET SPECIES)
PIGS:
Prevention
and
treatment
of
respiratory
disease
caused
by
_Actinobacillus _
_pleuropneumoniae, Mycoplasma hyopneumoniae, Pasteurella multocida _
and
other organisms sensitive to tilmicosin
RABBITS:
Prevention and treatment of respiratory disease caused by _Pasteurella
_
_multocida and Bordetella bronchiseptica, _susceptible to tilmicosin.
4.3.
CONTRAINDICATIONS
Horses or other _ Equidae_, must not be allowed access to feeds
containing
tilmicosin. Horses fed with tilmicosin medicated feeds may present
signs of
toxicity with lethargy, anorexia, reduction of feed consumption, loose
stools,
colic, distension of the abdomen and death.
Do not use in case of hypersensitivity to tilmicosin or to any of the
excipients.
Do not use in animals hypersensitive to tilmicosin and when there is
resistance
to tilmicosin or cross resistance to other macrolides like tylosin,
erythromycin or
lincomycin.
Revised: October 2014
AN: 01383/2013
Page 2 of 7
4.4.
SPECIAL WARNINGS (FOR EACH TARGET SPECIES)
With regard to the management of respiratory disease outbreaks, it
should be
noted that acutely ill animals are likely to be inappetant and
therefore require
parenteral treatment.
4.5.
SPECIAL PRECAUTIONS FOR USE
i)
Special precautions for use in animals
Inappropriate use of the product may increase the prevalence of
bacteria resistant to tilmicosin and may decrease the effectiveness of
treatment with tilmicosin related su
                                
                                Read the complete document